Hematologic and cytogenetic response to lenalidomide in de novo acute myeloid leukemia with chromosome 5q deletion
✍ Scribed by Maria J. Peñarrubia; Luz A. Silvestre; Joaquina Conde; Alberto Cantalapiedra; Luis J. Garcia Frade
- Publisher
- Elsevier Science
- Year
- 2009
- Tongue
- English
- Weight
- 150 KB
- Volume
- 33
- Category
- Article
- ISSN
- 0145-2126
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
In clinical practice, whether FISH for EGR1 in interphase nuclei has similar efficacy to detect deletion 5q anomalies as conventional cytogenetic studies is unknown. We compared conventional cytogenetics and FISH for 145 patients with deletion 5q and detected this anomaly by both methods in 144. Nin
We report on an adult patient with de novo acute myeloid leukemia (AML) with a t(11;22)(q23;q11.2) involving CDCREL1 and MLL genes. Reverse transcriptase (RT)-polymerase chain reaction (PCR) followed by direct sequencing analysis revealed the MLL-CDCREL1 fusion transcript in his leukemic cells. Anal
We investigated the prognostic significance of genetic polymorphism for glutathione S-transferase theta 1 (GSTT1) and glutathione S-transferase mu 1 (GSTM1) in 254 Chinese patients with de novo acute myeloid leukemia (AML) other than AML-M3. The early death rate after the initiation of chemotherapy
## Abstract ## BACKGROUND: A prognostic index to predict induction death in adult patients receiving induction chemotherapy for de novo acute myeloid leukemia (AML) was developed. ## METHODS: The authors analyzed 570 patients (aged 16‐70 years) included in 2 multicenter trials of the CETLAM Grou